Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04975308
Title A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Eli Lilly and Company
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | BEL | AUT


No variant requirements are available.